ArticleFrontiers in oncology2026
Gitogenin impedes tumorigenesis in hepatocellular carcinoma
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatocellular carcinoma (HCC), the most common primary malignant liver cancer, is associated with high incidence and mortality rates in China. Gitogenin (Gito), a saponin constituent in traditional Chinese medicine, exhibits significant pharmacological activity in promoting blood circulation and alleviating cerebral ischemia. However, the anti-HCC activity of Gito and its potential mechanism remain unknown. Methods: A series of in vitro and in vivo experiments, including MTT assay, colony formation assay, immunofluorescence (IF) staining, Western blot, wound healing assay, Transwell migration and invasion assays, as well as patient-derived xenograft (PDX) mouse models of hepatocellular carcinoma (HCC), were performed to assess the anti-hepatocellular carcinoma effects of Gito and elucidate its underlying mechanisms. Results: Our study found that Gito suppressed the growth and progression of HCC in vitro and in vivo by promoting autophagic processes and inhibiting epithelial-mesenchymal transition (EMT) and metastasis, likely through blocking the NUAK2/NF-κB axis. Autophagy inhibition reduced the inhibitory effects of Gito on the EMT, invasion, and migration of HCC cells. Additionally, NUAK2 overexpression weakened the inhibitory effect of Gito on the EMT, migration, and invasion of HCC cells, and the NF-κB axis. Gito treatment altered the melting curve of NUAK2 both in vitro and in vivo, suggesting that Gito may function as a potential inhibitor of NUAK2. Conclusion: Our research provides a scientific basis for Gito regulating autophagy, EMT, and the metastatic abilities of HCC cells by inhibiting the NUAK2/NF-κB axis, indicating that Gito may be a promising candidate drug for HCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.